Company Overview - Mirxes Holding Company Limited, also known as "觅瑞", is preparing for an IPO on the Hong Kong Stock Exchange, having received IPO filing approval in early 2025 [2] - The company was founded in 2014 and specializes in the development and commercialization of non-invasive blood-based miRNA tests for early cancer detection and other diseases [3] Financial Performance - Mirxes reported revenues of $17.76 million in 2022, projected to increase to $24.19 million in 2023 and $20.28 million in 2024 [5] - Gross profits for the same years were $9.33 million (52.5% gross margin), $13.58 million (56.2% gross margin), and $8.89 million (43.8% gross margin) respectively [5] - The company incurred losses of $56.20 million in 2022, $69.57 million in 2023, and is projected to lose $92.21 million in 2024 [6] Assets and Liabilities - As of December 31, 2024, Mirxes had total assets of $71.35 million and total liabilities of $269.60 million [7] - The company’s current liabilities amounted to $48.11 million, while non-current liabilities were $221.49 million [7] Cash Flow - The net cash used in operating activities was $48.68 million in 2022, $42.54 million in 2023, and projected to be $29.76 million in 2024 [8] - As of December 31, 2024, Mirxes had cash and cash equivalents of $5.07 million, indicating a tight liquidity position [8] Valuation and Funding - Mirxes has raised a total of $167 million through multiple funding rounds, with a current estimated valuation of $600 million [10][11] - The company completed a Series D funding round in July 2023, raising $50 million, with notable investors including Singapore's Economic Development Board and Mitsui & Co [11] Shareholding Structure - The largest shareholder is Central Road, owned by former Taobao CEO Sun Tongyu, holding 22.03% of the company [12] - Other significant shareholders include Dr. Zhu Xingfen (14.11%) and Dr. Zhou Lihan (8.12%) [12][16]
前淘宝总裁孙彤宇投的Mirxes冲刺港股：年亏9221万美元 获IPO备案
Sou Hu Cai Jing·2025-05-07 10:34